If I cannot afford Enhertu (trastuzumab deruxtecan), what alternative HER2‑targeted systemic therapy should I use?

Alternative HER2-Targeted Therapy When Enhertu Is Unaffordable

If you cannot afford Enhertu (trastuzumab deruxtecan), use trastuzumab emtansine (T-DM1) as your alternative second-line HER2-targeted therapy after progression on first-line trastuzumab and pertuzumab-based treatment.

Treatment Algorithm Based on Line of Therapy

First-Line Setting

If the patient has not yet received first-line therapy for metastatic disease (or recurred >12 months after adjuvant therapy):

• Use trastuzumab + pertuzumab + taxane (docetaxel or paclitaxel) 1, 2
• This remains the gold standard first-line regimen with high-quality evidence (Evidence quality: high; Strength: strong)
• Continue taxane for 4-6 months or until maximal response, then maintain dual HER2 blockade (trastuzumab + pertuzumab) until progression 1

Second-Line Setting

If the patient has progressed on first-line trastuzumab/pertuzumab-based therapy and cannot afford Enhertu:

• Use T-DM1 (trastuzumab emtansine) 1, 2, 3
• T-DM1 was the standard second-line therapy before Enhertu's approval, with strong evidence from the EMILIA trial showing median PFS of 9.6 months vs 6.4 months with lapatinib + capecitabine 4
• Evidence quality: high; Strength of recommendation: strong 1
• T-DM1 is specifically recommended when T-DXd (Enhertu) is unavailable 3

Third-Line and Beyond

If the patient has already received both trastuzumab/pertuzumab and T-DM1, or if T-DM1 is also unaffordable:

Option 1: Lapatinib + capecitabine 1

• Oral HER2-targeted therapy combination
• More affordable than ADCs
• Evidence-based option for third-line setting

Option 2: Trastuzumab + chemotherapy 1, 5

• Continue HER2 blockade with trastuzumab combined with different chemotherapy agents
• Multiple trials demonstrate benefit of continuing trastuzumab beyond progression 4
• Chemotherapy options include: vinorelbine, capecitabine, or other taxanes not previously used

Option 3: Dual HER2 blockade (trastuzumab + lapatinib) 1

• Can be used without chemotherapy in selected cases
• Particularly for patients with contraindications to chemotherapy

Special Considerations for Hormone Receptor-Positive Disease

If the patient has HR-positive/HER2-positive disease:

• Consider endocrine therapy + trastuzumab or lapatinib in selected cases 1, 3
• This is appropriate for patients with:
  • Low disease burden
  • Non-visceral or asymptomatic visceral disease
  • Contraindications to chemotherapy (e.g., cardiac dysfunction)
  • Long disease-free interval 1
• Evidence quality: high; Strength: moderate 1

Critical Timing Considerations

If patient completed adjuvant trastuzumab:

• ≤12 months before recurrence: Follow second-line recommendations (use T-DM1) 1, 2
• >12 months before recurrence: Follow first-line recommendations (use trastuzumab + pertuzumab + taxane) 1, 2

If patient received adjuvant trastuzumab + pertuzumab:

• Recurrence within 6-12 months: Treat according to second-line therapy (T-DM1) 6

Key Principles for Sequential Therapy

1. Always continue HER2-targeted therapy beyond progression 5, 4

   • Multiple trials demonstrate benefit of maintaining HER2 blockade even after progression on prior HER2-targeted regimens
   • The optimal duration is unknown, but continuation until further progression or unacceptable toxicity is standard

2. Add pertuzumab if not previously received 1, 4

   • If the patient progressed on trastuzumab alone (without pertuzumab), adding pertuzumab to trastuzumab ± chemotherapy is reasonable
   • Evidence from phase II studies shows objective response rate of 24.2% with dual blockade after trastuzumab failure 4

3. Sequence matters less than continuous HER2 blockade

   • There is no compelling evidence that combination chemotherapy regimens are superior to sequential single agents 5
   • The key is maintaining anti-HER2 therapy throughout treatment lines

Common Pitfalls to Avoid

Do not stop HER2-targeted therapy at progression: The evidence strongly supports continuing HER2 blockade through multiple lines of therapy 5, 4. Stopping trastuzumab at first progression is a common error that reduces survival.

Do not use anthracyclines with trastuzumab or pertuzumab: Concurrent use causes significant cardiac toxicity and should be avoided 5.

Do not delay treatment waiting for Enhertu access: Start with available effective alternatives immediately. Disease progression while waiting for drug access significantly worsens outcomes, as demonstrated in the ToGA trial where 216 of 810 patients became ineligible due to performance status deterioration while awaiting HER2 results 7.

Financial Assistance Resources

While not explicitly in the guidelines, explore:

• Patient assistance programs from manufacturers
• Clinical trial enrollment (if available)
• Biosimilar trastuzumab options (significantly less expensive than originator)

The evidence clearly establishes that T-DM1 is the appropriate alternative when Enhertu is unavailable or unaffordable in the second-line setting, with strong supporting data for efficacy and an established safety profile 1, 4, 2, 3.